This site is intended for healthcare professionals only
News
Share this article

Dementia risk and use of pioglitazone in T2D

It is thought that thiazolidinediones may have neuroprotective effects. Investigators examined a Taiwanese cohort of people with type 2 diabetes taking pioglitazone and matched them with controls. They found that the use of pioglitazone was associated with a reduced risk of dementia.

By Colin Kenny, GP, Dromore

In this study investigators examined 6401 people with diabetes who were being treated with pioglitazone and were registered on a Taiwanese health database. They compared them with 12,802 people with type 2 diabetes who were age- and sex-matched and who had never been treated with pioglitazone. Both cohorts were free from dementia at baseline.

In total, 113 (1.8%) and 323 (2.5%) patients in the pioglitazone-treated and comparison cohorts, respectively, developed dementia during the 5-year follow-up. The reduction in risk of dementia, after adjustment for age, sex, hypertension and stroke, was found to be 23% in the pioglitazone-treated cohort (compared with that in the comparison cohort). The investigators concluded that pioglitazone has a time- and dose-dependent protective association with dementia in people with diabetes.

To access the full publication, click here (log-in or purchase required)

Related content
Breastfeeding associated with lower CVD risk in high-risk women
;
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.

We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.